Phase II Study of Olaparib for BRCAness Phenotype in Pancreatic Cancer
Summary
The purpose of this phase II study is to determine the safety of olaparib and whether it can help to control metastatic pancreatic cancer in patients who are germline BRCA 1 or 2 negative and have a family history of breast, ovarian, pancreatic, gastric or prostate cancer in 2 or more first-degree relatives.
Biomarker testing to determine if patient is eligible for the trial must be completed prior to screening for the trial.
General Information
NCT#: NCT02677038
Study ID: 2015-0503
Trial Phase: Phase II
Trial Sponsor: AstraZeneca, M.D. Anderson Cancer Center
Therapies Used in This Trial: Olaparib